Related Experiment Video

Updated: Feb 8, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.7K

Risk of retinal vein occlusions in patients taking systemic tyrosine kinase inhibitors

Nitesh Mohan1,2, Sunil K Srivastava1, Chandni Duphare1

  • 1Cole Eye Institute, Cleveland Clinic, Cleveland, OH, USA.

Eye (London, England)
|February 6, 2026
PubMed
Abstract

Insights

This study found a probable link between tyrosine kinase inhibitor (TKI) therapy and retinal vein occlusion (RVO). Patients on TKIs, especially those with vascular risk factors, require careful monitoring for RVO development.

Area of Science:

  • Ophthalmology
  • Oncology
  • Pharmacology

Background:

  • Tyrosine kinase inhibitors (TKIs) are crucial in treating systemic malignancies.
  • Retinal vein occlusion (RVO) is a serious ocular vascular event.
  • The potential ocular side effects of TKIs warrant investigation.

Purpose of the Study:

  • To investigate the occurrence of RVO in patients undergoing TKI therapy for cancer.
  • To identify characteristics and outcomes of RVO in this patient cohort.

Main Methods:

  • Retrospective chart review of patients treated with TKIs from 2014-2024.
  • Data collection included demographics, cancer type, TKI details, ocular history, and outcomes.
  • Ophthalmic imaging was reviewed to confirm RVO diagnoses.

Main Results:

  • Eleven patients (12 eyes) developed RVO during TKI treatment.
  • Common TKIs involved were imatinib, axitinib, ibrutinib, and regorafenib.
  • The mean Naranjo score suggested a probable association between TKI use and RVO.

Conclusions:

  • A potential association exists between TKI therapy and the development of RVO.
  • Increased awareness is crucial for patients on TKIs, particularly those with existing vascular risk factors.

More Related Videos

Optimization of the Retinal Vein Occlusion Mouse Model to Limit Variability07:23

Optimization of the Retinal Vein Occlusion Mouse Model to Limit Variability

Published on: August 6, 2021

3.2K
Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

8.4K

Related Concept Videos

Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
18.9K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
550
Overview of Systemic Veins01:11

Overview of Systemic Veins

Systemic veins are crucial blood vessels that return deoxygenated blood from various body tissues back to the heart. There are three systemic veins that return deoxygenated blood to the heart, they are as follows.
The coronary sinus, the heart's principal vein, resides in the coronary sulcus on the heart's posterior aspect. This broad venous channel receives nearly all venous blood from the myocardium, the heart muscle. It is fed by three primary veins: the great cardiac vein, the...
1.3K
Protein Kinases and Phosphatases02:54

Protein Kinases and Phosphatases

Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
15.2K
Protein Kinases and Phosphatases02:54

Protein Kinases and Phosphatases

4.5K
Eukaryotic Transcription Inhibitors01:52

Eukaryotic Transcription Inhibitors

Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
11.0K